Archived Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care - Prostate Cancer
Clinicians need up-to-date information about when and how to use molecular assays to inform individual patient risk; the side effects of ADT and management options for these side effects; and the results of recent clinical trials in the non-metastatic CRPC setting, so that patients can receive optimal care and delay the onset of metastases as long as possible.
Category
  • Prostate Cancer
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • CCM clock hours
  • Participation
NCCN Guidelines® Insights - Prostate Cancer, Version 1.2021
The NCCN Guidelines for Prostate Cancer address staging and risk assessment after a prostate cancer diagnosis and include management options for localized, regional, and metastatic disease. This article summarizes the panel’s discussions for the 2021 update of the guidelines with regard to systemic therapy for metastatic castration-resistant prostate cancer.
Category
  • Prostate Cancer
Format
  • Monograph/Journal Supplement
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Multidisciplinary Treatment of Prostate Cancer
Optimal treatment of prostate cancer requires a multidisciplinary team approach, with expertise needed in medical oncology, radiation oncology, urology, genetics, pathology, diagnostic radiology, and supportive care. It is important for clinicians who treat patients with prostate cancer to understand all facets of comprehensive care so that their patients receive the best possible treatments with effective management of side effects.
Category
  • Prostate Cancer
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation